Lo Chia-Yun, Wu Zhengqi, Misplon Julia A, Price Graeme E, Pappas Claudia, Kong Wing-Pui, Tumpey Terrence M, Epstein Suzanne L
Center for Biologics Evaluation and Research, Food and Drug Administration , Rockville, MD 20852-1448, USA.
Vaccine. 2008 Apr 16;26(17):2062-72. doi: 10.1016/j.vaccine.2008.02.047. Epub 2008 Mar 13.
Influenza epidemics or pandemics can arise for which strain- or subtype-matched vaccines are unavailable. Heterosubtypic immunity (Het-I) targeting conserved influenza A antigens could reduce morbidity and mortality during preparation of matched vaccines. Various vaccines inducing Het-I in animals have been studied separately using different viruses and conditions, but effectiveness for inducing Het-I has not been directly compared. The present studies compared immunization with cold-adapted (ca) viruses to DNA prime-recombinant adenovirus (rAd) boost vaccination to conserved antigens nucleoprotein (NP), matrix-2 (M2), or A/NP+M2. Both ca and DNA-rAd vaccinations induced antibody and T cell responses, and protected against lethal H1N1 challenge. Only A/NP+M2 DNA-rAd protected against challenge with highly pathogenic A/Vietnam/1203/2004 (H5N1); ca vaccine did not. Existing ca vaccines may provide some Het-I, but experimental vaccination focusing on conserved antigens was more effective in this model for protection against a divergent, highly pathogenic virus.
流感流行或大流行可能会出现,而此时可能没有与毒株或亚型匹配的疫苗。针对保守甲型流感抗原的异源亚型免疫(Het-I)可在制备匹配疫苗期间降低发病率和死亡率。使用不同病毒和条件分别研究了多种在动物中诱导Het-I的疫苗,但尚未直接比较诱导Het-I的有效性。本研究比较了用冷适应(ca)病毒免疫与DNA初免-重组腺病毒(rAd)加强免疫针对保守抗原核蛋白(NP)、基质2(M2)或A/NP+M2的效果。ca免疫和DNA-rAd免疫均诱导了抗体和T细胞反应,并对致死性H1N1攻击具有保护作用。只有A/NP+M2 DNA-rAd对高致病性A/越南/1203/2004(H5N1)攻击具有保护作用;ca疫苗则没有。现有的ca疫苗可能提供一些Het-I,但在该模型中,针对保守抗原的实验性免疫在预防不同的高致病性病毒方面更有效。